Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of “Buy” by Brokerages

Trevi Therapeutics, Inc. (NASDAQ:TRVI) has received an average rating of “Buy” from the ten research firms that are covering the company, MarketBeat reports. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $9.31.

A number of equities research analysts have commented on TRVI shares. HC Wainwright lifted their target price on Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a research report on Thursday, December 12th. D. Boral Capital restated a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a report on Wednesday, January 8th. B. Riley reaffirmed a “buy” rating and set a $6.00 target price on shares of Trevi Therapeutics in a research note on Monday, October 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $8.00 price target on shares of Trevi Therapeutics in a research note on Thursday, December 12th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. MAI Capital Management lifted its holdings in Trevi Therapeutics by 0.7% during the 3rd quarter. MAI Capital Management now owns 1,327,285 shares of the company’s stock worth $4,433,000 after buying an additional 8,789 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Trevi Therapeutics by 10.2% during the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock worth $4,223,000 after acquiring an additional 117,418 shares during the period. State Street Corp raised its stake in shares of Trevi Therapeutics by 5.9% in the third quarter. State Street Corp now owns 952,912 shares of the company’s stock valued at $3,183,000 after acquiring an additional 53,051 shares in the last quarter. Acuta Capital Partners LLC boosted its holdings in Trevi Therapeutics by 11.7% in the third quarter. Acuta Capital Partners LLC now owns 290,500 shares of the company’s stock valued at $970,000 after purchasing an additional 30,500 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in Trevi Therapeutics during the 3rd quarter worth $409,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Trading Down 2.0 %

Trevi Therapeutics stock opened at $3.91 on Monday. The company has a 50-day moving average price of $3.58 and a 200 day moving average price of $3.22. Trevi Therapeutics has a 12-month low of $1.31 and a 12-month high of $4.68. The stock has a market cap of $300.55 million, a P/E ratio of -8.89 and a beta of 0.87.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same period last year, the business posted ($0.08) EPS. As a group, analysts forecast that Trevi Therapeutics will post -0.49 EPS for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.